MedTrace Logo

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3

NCT00000354 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

Conditions

  • Opioid-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Lofexidine

Sponsors & Collaborators

Principal Investigators

  • Charles O'Brien, M.D., Ph.D. · PDVAMC Treatment Research Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
21 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-07-31
Primary Completion
1997-09-30
Completion
1997-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000354 on ClinicalTrials.gov